PD-L1 expression and CD8+ infiltration shows heterogeneity in juvenile recurrent respiratory papillomatosis.

[1]  S. M. García,et al.  2014: , 2020, A Party for Lazarus.

[2]  윤재량.  2004 , 2019, The Winning Cars of the Indianapolis 500.

[3]  蕭瓊瑞撰述,et al.  2009 , 2019, The Winning Cars of the Indianapolis 500.

[4]  S. Hewitt,et al.  2008 , 2018, Los 25 años de la OMC: Una retrospectiva fotográfica.

[5]  S. Hewitt,et al.  2007 , 2018, Los 25 años de la OMC: Una retrospectiva fotográfica.

[6]  Florence March,et al.  2016 , 2016, Affair of the Heart.

[7]  M. Mino‐Kenudson.  Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer? , 2016, Cancer biology & medicine.

[8]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[9]  G. Freeman,et al.  Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. , 2016, Cancer research.

[10]  N. Matsumura,et al.  PD-1/PD-L1 blockade in cancer treatment: perspectives and issues , 2016, International Journal of Clinical Oncology.

[11]  Xue Han,et al.  Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. , 2015, The Journal of clinical investigation.

[12]  A. Ribas.  Adaptive Immune Resistance: How Cancer Protects from Immune Attack. , 2015, Cancer discovery.

[13]  C. Martin.  2015 , 2015, Les 25 ans de l’OMC: Une rétrospective en photos.

[14]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[15]  S. Rosenberg,et al.  Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Bouček,et al.  Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma , 2015, Oncoimmunology.

[17]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[18]  P. Sharma,et al.  PD-L1 Expression in Triple-Negative Breast Cancer , 2014, Cancer Immunology Research.

[19]  Hong-wei Wang,et al.  Increased expression of programmed death (PD)‐1 and its ligand PD‐L1 correlates with impaired cell‐mediated immunity in high‐risk human papillomavirus‐related cervical intraepithelial neoplasia , 2013, Immunology.

[20]  J. Taube,et al.  Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. , 2013, Cancer research.

[21]  Pramodita Sharma.  2012 , 2013, Les 25 ans de l’OMC: Une rétrospective en photos.

[22]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[23]  A. James.  2010 , 2011, Philo of Alexandria: an Annotated Bibliography 2007-2016.

[24]  C. Kalkman,et al.  Behavior and Development in Children and Age at the Time of First Anesthetic Exposure , 2009, Anesthesiology.

[25]  W. Barbaresi,et al.  Early Exposure to Anesthesia and Learning Disabilities in a Population-based Birth Cohort , 2009, Anesthesiology.

[26]  M. Wasik,et al.  Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) , 2008, Proceedings of the National Academy of Sciences.

[27]  B. Wiatrak,et al.  Recurrent Respiratory Papillomatosis: A Review , 2008, The Laryngoscope.

[28]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[29]  N. Chadha,et al.  Antiviral agents for the treatment of recurrent respiratory papillomatosis: A systematic review of the English-language literature , 2007, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[30]  D. Kimberlin.  Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis. , 2004, Antiviral research.

[31]  A. Piperno,et al.  2003 , 2003, Intensive Care Medicine.

[32]  W. Reeves,et al.  National registry for juvenile-onset recurrent respiratory papillomatosis. , 2003, Archives of otolaryngology--head & neck surgery.

[33]  신애자,et al.  1998 , 2001, The Winning Cars of the Indianapolis 500.

[34]  H. Kashima,et al.  A Staging System for Assessing Severity of Disease and Response to Therapy in Recurrent Respiratory Papillomatosis , 1998, The Laryngoscope.

[35]  Marc Mézard,et al.  1993 , 1993, The Winning Cars of the Indianapolis 500.

[36]  R. Hruban,et al.  Sites of Predilection in Recurrent Respiratory Papillomatosis , 1993, The Annals of otology, rhinology, and laryngology.

[37]  金繁雄.  1986 , 1986, Qatar 1975/76-2019.

[38]  Patrice Ravel,et al.  PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. , 2013, Cancer research.

[39]  I. Hampson,et al.  The role of HPV type in Recurrent Respiratory Papillomatosis. , 2010, International journal of pediatric otorhinolaryngology.

[40]  P. Mischel,et al.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma , 2007, Nature Medicine.